Simultaneous determination of a novel antitrypanosomal compound (OSU-36) and its ester derivative (OSU-40) in plasma by HPLC: Application to first pharmacokinetic study in rats

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 1, 2011, Pages 36-45

  Gershkovich, Pavel ^a   Wasan, Kishor M ^a   Sivak, Olena ^a   Lysakowski, Summer ^a   Reid, Carolyn ^b   Premalatha, Kokku ^b   Werbovetz, Karl A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 1,2 DIHYDRO 2,2,4 TRIMETHYLQUINOLIN 6 OL HYDROCHLORIDE; 1 BENZYL 1,2 DIHYDRO 2,2,4 TRIMETHYLQUINOLIN 6 YL ACETATE; ACETONITRILE; ANTITRYPANOSOMAL AGENT; ASCORBIC ACID; ESTER DERIVATIVE; ESTERASE; ESTERASE INHIBITOR; OSU 36; OSU 40; PARAOXON; PRODRUG; UNCLASSIFIED DRUG; WATER;

ACCURACY; AEROBIC METABOLISM; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; EVAPORATION; FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRECIPITATION; QUALITY CONTROL; RAT; ROOM TEMPERATURE; ULTRAVIOLET SPECTROSCOPY;

EID: 79951804817     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3cp4s     Document Type: Article

References (13)

1. Fotie J, Kaiser M, Delfin DA, Manley J, Reid CS, Paris JM, et al. Antitrypanosomal activity of 1,2- dihydroquinolin-6-ols and their ester derivatives. J Med Chem 2010;53(3):966-82.
2. Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. Parasit Vectors 2010;3(1):15.
3. Fevre EM, Wissmann BV, Welburn SC, Lutumba P. The burden of human African trypanosomiasis. PLoS Negl Trop Dis 2008;2(12):e333.
4. Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol 2009;211(1-2):16-22.
5. WHO. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly. Epidemiol. Rec. 2006;81:71-80.
6. Welburn SC, Maudlin I, Simarro PP. Controlling sleeping sickness - a review. Parasitology 2009;136(14):1943-9.
7. Reid CS, Patrick DA, He S, Fotie J, Premalatha K, Tidwell RR, et al. Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2- dihydroquinolin-6-ols: Effect of core substitutions and salt formation. Bioorg Med Chem 2011;19(1):513-23.
8. Karnes HT, March C. Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis. Pharm Res 1993;10(10):1420-6.
9. Liederer BM, Borchardt RT. Stability of oxymethylmodified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J Pharm Sci 2005;94(10):2198-206.
10. Yoshigae Y, Imai T, Taketani M, Otagiri M. Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma. Chirality 1999;11(1):10-3.
11. Zeng J, Onthank D, Crane P, Unger S, Zheng N, Pasas-Farmer S, et al. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry-- evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile estercontaining drug. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852(1-2):77-84.
12. Hugh D, Grennan A, Abugila MA, Weinkove C. Ascorbic acid as an antioxidant in measurements of catecholamines in plasma. Clin Chem 1987;33(4):569-71.
13. Le Guellec C, Gaudet ML, Lamanetre S, Breteau M. Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies. Ther Drug Monit 1997;19(6):669-74.